P/E ratio for Glaukos (GKOS)
P/E ratio as of April 2024 (TTM): -37.0
According to Glaukos's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -36.9814. At the end of 2022 the company had a P/E ratio of -20.9.
P/E ratio history for Glaukos from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -20.9 | -49.21% |
| 2021 | -41.1 | 49.26% |
| 2020 | -27.6 | -117.21% |
| 2019 | 160 | -205.53% |
| 2018 | -152 | -100% |
| 2017 | < -1000 | -1.4439626312011E+18% |
| 2016 | 256 | -11632.49% |
| 2015 | -2.22 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ICU Medical
ICUI | -47.0 | 26.96% | 🇺🇸 USA |
 AtriCure ATRC | -42.9 | 16.02% | 🇺🇸 USA |
 Integra LifeSciences IART | 23.2 | -162.81% | 🇺🇸 USA |
 Hill-Rom HRC | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.